The The open medical value for new drug marketing.

There are some open movements in innovation, society and government (1-1). Traditionally, our access has been limited in any society and organization. However, the open movements have recently provided us broad accessibility, and we can easily connect with everybody and everything through these new technologies. The accessibility is empowering individuals and organizational transparency, therefore, we will have an effect on each other exerting greater personal influence over organizations and participate in more digital activities as they conduct their daily lives (1-2). Under the circumstances, consumers have the most influence on business strategy at the present. In the same way, patients will expect to gain even more power and influence over the new medical markets. The open-source activity is typically viewed as a cooperative approach method in product development. I think that it is very useful for the new open medical market, and it is important for the medical industry to create a robust, secure and reliable operating system. Open source approaches can provide these open cooperative systems for medical institutions and patients efficiently. The direction for open source will provide the medical industry with a mechanism to compete with leading manufactures. Indeed, the relevant authorities, such as FDA (The U.S. Food and Drug Administration) and EMA (The European Medicines Agency), will aim at exploring the medical field how to find economic and social promotion for sustainable innovation models with more openness, easier accessibility, and higher result-oriented efficiency. There are new noteworthy movements in clinical trials to get to look at the raw information behind statistical studies such as a big data analysis( 1-3). The aim is to share the medical trial data with openness and accessibility. The open source strategy is going to provide a new framework for medical research and innovation (1-4). One example is the YODA project that is planed by Yale university and J&J to create an autonomous process in offering information. It will extend its commitment to sharing clinical trials data to enhance public health and advance science and medicine. Daring data from clinical trials is critical to advance public health because it furthers our understanding of disease, expands the base of knowledge needed to develop new treatments, and generates new insights and more complete evidence to enable better healthcare decisions for patient. Besides, developing science and technology would change the concept of diagnoses (1-5). For example, "Precision Medicine" will lead to hospitals and medical industries to be more productive, patients will acquire the opportunity for a treatment using the most effective drug. It will also reform the medical system for the cost reduction in the point of making various improvements in the patient's QOL.

On the other hand, the expectation of the growth in the medical industry may come to a standstill because it is going to be difficult to create new drugs rising a higher level of safety and effectiveness for drugs. In addition, the social security system will be reexamined because of fiscal policy for an aging society. This situation in lack of revenue are not able to keep a healthcare system for the future generation, serious global issues are the impacts on the social medical system. Thus, the companies in the medical industry must struggle with how they grow in the new medical market.

Under the hard circumstances, the open source approach will provide a blended model with attributes from both the developer of medical drugs, medical devices and patients. In other words, the open medical systemization will provide the medical standardization such as the value-based purchasing program that will lead a medical activity to the financial process (1-6). In particular, new medical devices such as wearable medical devices will change the traditional concept of diagnosis and medical treatments to a numerical value because the process will be able to increase productivity and reduce medical expenses to promote the financial process (1-7). Thus, it is important for the future to create a valuational method for medical treatment in drug's market.

Consequently, the open source will provide the core universal value of openness and knowledge sharing. The final decision of patient on data sharing will change their attitudes for treatment, the right of medical decision will transfer the patient options like as a marketable information (1-8). The option can provide patient to make decision of the individual medical choice, at the same time. That will be under pressure to reduce cost in medical fields systematically. The open movement such as medical open data access will trigger the new open medical market for patient beyond barriers of geopolitics and diversity of medical markets.

Reference

1-1) An Analysis of Open Source Business Models., IBM is committed to Linux and Open Source. [IBM(LXB03001USEN)]., Open Government Data (OECD Working Papers on Public Governance No. 22).

1-2) Competitive Strategy for Open Source Software (Marketing Science., 2011,Vol. 30, No. 6, p1066-1078)

1-3) Performance of a web-based clinical diagnosis support system for internists. (J Gen intern Med., 2008, 23, 37-40).

1-4) A model for dissemination and independent analysis of industry data (JAMA. 2011., 12, 306, p1593-1594)., Publication of NIH funded trials registered in Clinical Trials. gov: cross sectional analysis. (BMJ., 2011, 344, d7292 doi: 10.1136/bmj. d7292)., The Medicare Physician-Data Release- Context and Rationale., (The New England Journal of Medicine., 2014, June 11, 1-3)

1-5) Paving the Way for Personalized Medicine., Evidence-Based Medicine in the EMR Era (The New England Journal of Medicine., 2011, Novmber 3, 1-2)., Personalized Medicine. (McKinsey & Company)., Toward Precision Medicine. (The National Academies Press)., Preparing for Personalized Medicine in Massachusetts. (Harvard University Institute of Politics)

1-6) Effect of financial incentives on incentivised and non-incentivised clinical activities: longitudinal analysis of data from the UK Quality and Outcomes Frameworks. (BMJ., 2011, 342, d3590., doi: 10.1136/bmj.d3590)., The impact of removing financial incentives from clinical quality indicators: longitudinal analysis of four kaiser Permanente indicators. (BMJ., 2010, 340, c1898., doi:10.1136/bmj.c1898)., Reliability of patient responses in pay for performance schemes: analysis of national General Practitioner Patient Survey data in England. (BMJ., 2009, 339, b3851., doi:10.1136/bmj.b3851)., ?Exclusion of Patients from Pay-for-Performance Targets by English Physicians. (N. ENGL MED., 2008, 359, 274)?.

1-7) Improving Health care through Mobile Medical Devices and Sensors. (BROOKINGS., October 2013).

1-8) Challenges to the credibility of patient feedback in primary healthcare settings. (British Journal of General Practice, 2013, March, 200-208.)